2020.Sep.28
Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: Not applicable Cause of occurrence: Bispecific antibody drug is one of the mainstreams in new generation antibody drug. Currently, only a few bispecific antibody drugs, none […]
This article is password protected.
To view the content, please enter your password in the field below